MicroRNA-485 plays tumour-suppressive roles in colorectal cancer by directly targeting GAB2 Retraction in /10.3892/or.2022.8274

Li,Jibin; Xu,Jian; Yan,Xiaofei; Jin,Keer; Li,Wenya; Zhang,Rui

doi:10.3892/or.2018.6449

MicroRNA-485 plays tumour-suppressive roles in colorectal cancer by directly targeting GAB2

Retraction in: /10.3892/or.2022.8274

Authors:
- Jibin Li
- Jian Xu
- Xiaofei Yan
- Keer Jin
- Wenya Li
- Rui Zhang
View Affiliations

Affiliations: Department of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China
Published online on: May 17, 2018 https://doi.org/10.3892/or.2018.6449
Pages: 554-564

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is reported to be the third most common cancer and the fourth leading cause of cancer-related deaths around the world. MicroRNA-485 (miR-485) has been reported to be aberrantly expressed and play important roles in several types of human malignancy. However, the expression level, biological functions and underlying molecular mechanisms of miR-485 in CRC remain unclear. Therefore, the aim of the present study was to determine miR-485 expression levels and their clinical significance in CRC and to explore the functions and underlying mechanisms of miR-485 in this disease. In the present study, miR-485 was lowly expressed in CRC tissues and cell lines. Decreased miR-485 expression was associated with tumour size, lymph node metastasis, distant metastasis and TNM stage. Functional assays indicated that upregulation of miR-485 impaired CRC cell proliferation, invasion and induced cell apoptosis. Grb2-associated binding 2 (GAB2) was identified as a direct target of miR-485 in CRC. GAB2 was upregulated in CRC tissues and was negatively correlated with the miR-485 expression level. Furthermore, GAB2 knockdown simulated the tumour-suppressing roles of miR-485 overexpression in CRC cells. Moreover, restored GAB2 expression reversed the effects of miR-485 overexpression in CRC cells. In addition, miR-485 suppressed the AKT and ERK signalling pathways in CRC by directly targeting GAB2. Collectively, these findings demonstrate that miR-485 may play tumour suppressive roles in CRC by directly targeting GAB2 and indirectly regulating AKT and ERK signalling pathways, suggesting that miR-485 may be a potential therapeutic target for patients with this disease.

View Figures

View References

1	Brenner H, Kloor M and Pox CP: Colorectal cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
3	Andrews L: Dietary flavonoids for the prevention of colorectal cancer. Clin J Oncol Nurs. 17:671–672. 2013. View Article : Google Scholar : PubMed/NCBI
4	Altobelli E, Lattanzi A, Paduano R, Varassi G and di Orio F: Colorectal cancer prevention in Europe: Burden of disease and status of screening programs. Prev Med. 62:132–141. 2014. View Article : Google Scholar : PubMed/NCBI
5	Sugarbaker PH: Colorectal cancer: Prevention and management of metastatic disease. BioMed Res Int. 2014:7828902014. View Article : Google Scholar : PubMed/NCBI
6	Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA and Levin TR: Guidelines for colonoscopy surveillance after screening and polypectomy: A consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 143:844–857. 2012. View Article : Google Scholar : PubMed/NCBI
7	Malafosse R, Penna C, Cunha Sa A and Nordlinger B: Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol. 12:887–894. 2001. View Article : Google Scholar : PubMed/NCBI
8	Dong-Xu W, Jia L and Su-Juan Z: MicroRNA-185 is a novel tumor suppressor by negatively modulating the Wnt/β-catenin pathway in human colorectal cancer. Indian J Cancer. 52 Suppl 3:E182–E185. 2015. View Article : Google Scholar : PubMed/NCBI
9	Qiu Y, Liu Q, Chen G, Wang W, Peng K, Xiao W and Yang H: Outcome of rectal cancer surgery in obese and nonobese patients: A meta-analysis. World J Surg Oncol. 14:232016. View Article : Google Scholar : PubMed/NCBI
10	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
11	Valencia-Sanchez MA, Liu J, Hannon GJ and Parker R: Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
12	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
13	Donadeu FX, Schauer SN and Sontakke SD: Involvement of miRNAs in ovarian follicular and luteal development. J Endocrinol. 215:323–334. 2012. View Article : Google Scholar : PubMed/NCBI
14	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
15	Rutnam ZJ and Yang BB: The involvement of microRNAs in malignant transformation. Histol Histopathol. 27:1263–1270. 2012.PubMed/NCBI
16	Xie M, Qin H, Luo Q, Huang Q, He X, Yang Z, Lan P and Lian L: MicroRNA-30a regulates cell proliferation and tumor growth of colorectal cancer by targeting CD73. BMC Cancer. 17:3052017. View Article : Google Scholar : PubMed/NCBI
17	Zhang S, Yin WL, Zhang X and Zhang XY: MicroRNA-455 is downregulated in gastric cancer and inhibits cell proliferation, migration and invasion via targeting insulin-like growth factor 1 receptor. Mol Med Rep. 16:3664–3672. 2017. View Article : Google Scholar : PubMed/NCBI
18	Liu PL, Liu WL, Chang JM, Chen YH, Liu YP, Kuo HF, Hsieh CC, Ding YS, Chen WW and Chong IW: MicroRNA-200c inhibits epithelial-mesenchymal transition, invasion, and migration of lung cancer by targeting HMGB1. PLoS One. 12:e01808442017. View Article : Google Scholar : PubMed/NCBI
19	Zhang H, Yan T, Liu Z, Wang J, Lu Y, Li D and Liang W: MicroRNA-137 is negatively associated with clinical outcome and regulates tumor development through EZH2 in cervical cancer. J Cell Biochem. 119:938–947. 2018. View Article : Google Scholar : PubMed/NCBI
20	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
21	Ye L, Wang H and Liu B: miR-211 promotes non-small cell lung cancer proliferation by targeting SRCIN1. Tumour Biol. 37:1151–1157. 2016. View Article : Google Scholar : PubMed/NCBI
22	Miyoshi J, Toden S, Yoshida K, Toiyama Y, Alberts SR, Kusunoki M, Sinicrope FA and Goel A: MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep. 7:433932017. View Article : Google Scholar : PubMed/NCBI
23	Kim TH, Kim YK, Kwon Y, Heo JH, Kang H, Kim G and An HJ: Deregulation of miR-519a, 153, and 485–5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology. 57:734–743. 2010. View Article : Google Scholar : PubMed/NCBI
24	Chen Z, Li Q, Wang S and Zhang J: miR-485-5p inhibits bladder cancer metastasis by targeting HMGA2. Int J Mol Med. 36:1136–1142. 2015. View Article : Google Scholar : PubMed/NCBI
25	Anaya-Ruiz M, Bandala C and Perez-Santos JL: miR-485 acts as a tumor suppressor by inhibiting cell growth and migration in breast carcinoma T47D cells. Asian Pac J Cancer Prev. 14:3757–3760. 2013. View Article : Google Scholar : PubMed/NCBI
26	Lou C, Xiao M, Cheng S, Lu X, Jia S, Ren Y and Li Z: MiR-485-3p and miR-485-5p suppress breast cancer cell metastasis by inhibiting PGC-1α expression. Cell Death Dis. 7:e21592016. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Ding C, Luo J, Fan X, Li L, Li S, Wen K, Feng J and Wu G: Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels. J Exp Clin Cancer Res. 36:562017. View Article : Google Scholar : PubMed/NCBI
29	Ding C, Luo J, Yu W, Gao S, Yang L, Chen C and Feng J: Gab2 is a novel prognostic factor for colorectal cancer patients. Int J Clin Exp Pathol. 8:2779–2786. 2015.PubMed/NCBI
30	Matsumura T, Sugimachi K, Takahashi Y, Uchi R, Sawada G, Ueda M, Hirata H, Sakimura S, Ueo H, Takano Y, et al: Clinical significance of GAB2, a scaffolding/docking protein acting downstream of EGFR in human colorectal cancer. Ann Surg Oncol. 21 Suppl 4:S743–S749. 2014. View Article : Google Scholar : PubMed/NCBI
31	Gu DH, Mao JH, Pan XD, Zhu H, Chen X, Zheng B and Shan Y: microRNA-302c-3p inhibits renal cell carcinoma cell proliferation by targeting Grb2-associated binding 2 (Gab2). Oncotarget. 8:26334–26343. 2017.PubMed/NCBI
32	Xu LJ, Wang YC, Lan HW, Li J and Xia T: Grb2-associated binder-2 gene promotes migration of non-small cell lung cancer cells via Akt signaling pathway. Am J Transl Res. 8:1208–1217. 2016.PubMed/NCBI
33	Chen Y, Liu Q, Wu M, Li M, Ding H, Shan X, Liu J, Tao T, Ni R and Chen X: GAB2 promotes cell proliferation by activating the ERK signaling pathway in hepatocellular carcinoma. Tumour Biol. 37:11763–11773. 2016. View Article : Google Scholar : PubMed/NCBI
34	Zhang G, Zhou H, Xiao H, Liu Z, Tian H and Zhou T: MicroRNA-92a functions as an oncogene in colorectal cancer by targeting PTEN. Dig Dis Sci. 59:98–107. 2014. View Article : Google Scholar : PubMed/NCBI
35	Gao F and Wang W: MicroRNA-96 promotes the proliferation of colorectal cancer cells and targets tumor protein p53 inducible nuclear protein 1, forkhead box protein O1 (FOXO1) and FOXO3a. Mol Med Rep. 11:1200–1206. 2015. View Article : Google Scholar : PubMed/NCBI
36	Rothschild SI: Epigenetic therapy in lung cancer - Role of microRNAs. Front Oncol. 3:1582013. View Article : Google Scholar : PubMed/NCBI
37	Mou X and Liu S: MiR-485 inhibits metastasis and EMT of lung adenocarcinoma by targeting Flot2. Biochem Biophys Res Commun. 477:521–526. 2016. View Article : Google Scholar : PubMed/NCBI
38	Jing LL and Mo XM: Reduced miR-485-5p expression predicts poor prognosis in patients with gastric cancer. Eur Rev Med Pharmacol Sci. 20:1516–1520. 2016.PubMed/NCBI
39	Guo GX, Li QY, Ma WL, Shi ZH and Ren XQ: MicroRNA-485-5p suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting stanniocalcin 2. Int J Clin Exp Pathol. 8:12292–12299. 2015.PubMed/NCBI
40	Sun X, Liu Y, Li M, Wang M and Wang Y: Involvement of miR-485-5p in hepatocellular carcinoma progression targeting EMMPRIN. Biomed Pharmacother. 72:58–65. 2015. View Article : Google Scholar : PubMed/NCBI
41	Formosa A, Markert EK, Lena AM, Italiano D, Finazzi-Agro' E, Levine AJ, Bernardini S, Garabadgiu AV, Melino G and Candi E: MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene. 33:5173–5182. 2014. View Article : Google Scholar : PubMed/NCBI
42	Wu J, Li J, Ren J and Zhang D: MicroRNA-485-5p represses melanoma cell invasion and proliferation by suppressing Frizzled7. Biomed Pharmacother. 90:303–310. 2017. View Article : Google Scholar : PubMed/NCBI
43	Lin XJ, He CL, Sun T, Duan XJ, Sun Y and Xiong SJ: hsa-miR-485-5p reverses epithelial to mesenchymal transition and promotes cisplatin-induced cell death by targeting PAK1 in oral tongue squamous cell carcinoma. Int J Mol Med. 40:83–89. 2017. View Article : Google Scholar : PubMed/NCBI
44	Kang M, Ren MP, Zhao L, Li CP and Deng MM: miR-485-5p acts as a negative regulator in gastric cancer progression by targeting flotillin-1. Am J Transl Res. 7:2212–2222. 2015.PubMed/NCBI
45	Yart A, Mayeux P and Raynal P: Gab1, SHP-2 and other novel regulators of Ras: Targets for anticancer drug discovery? Curr Cancer Drug Targets. 3:177–192. 2003. View Article : Google Scholar : PubMed/NCBI
46	Gu H and Neel BG: The ‘Gab’ in signal transduction. Trends Cell Biol. 13:122–130. 2003. View Article : Google Scholar : PubMed/NCBI
47	Lee SH, Jeong EG, Nam SW, Lee JY, Yoo NJ and Lee SH: Increased expression of Gab2, a scaffolding adaptor of the tyrosine kinase signalling, in gastric carcinomas. Pathology. 39:326–329. 2007. View Article : Google Scholar : PubMed/NCBI
48	Duckworth C, Zhang L, Carroll SL, Ethier SP and Cheung HW: Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression. Oncogene. 35:4036–4047. 2016. View Article : Google Scholar : PubMed/NCBI
49	Fleuren ED, O'Toole S, Millar EK, McNeil C, Lopez-Knowles E, Boulghourjian A, Croucher DR, Schramek D, Brummer T, Penninger JM, et al: Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development. Int J Cancer. 127:1486–1492. 2010. View Article : Google Scholar : PubMed/NCBI